Ключевые слова:
хронический миелолейкоз; молекулярный ответ; BCR-ABL1; международная шкала (IS); иматиниб; ELN 2020; количественная ПЦР; ингибиторы тирозинкиназы; мониторинг терапии.Библиографические ссылки
Baccarani M., Deininger M. W., Rosti G. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2020 update. Blood. 2020; 135(12): 1054–1067
Branford S., Hughes T. P., Cornelissen J. J. et al. Recommendations for the implementation of standardized molecular monitoring for chronic myeloid leukemia. Blood. 2019; 133(20): 2052–2060.
Clark R. E., Polydoros F., Apperley J. F. et al. Deeper molecular response in chronic myeloid leukemia and treatment-free remission. Haematologica. 2019; 104(11): 2144–2151
Cross N. C. P., White H. E., Muller M. C. et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26(10): 2172–2175.
Deininger M. W., Goldman J. M., Melo J. V. The molecular biology of chronic myeloid leukemia. Blood. 2000; 96(10): 3343–3356.
Gabert J., Beillard E., van der Velden V. H. et al. Standardization and quality control studies of real-time quantitative RT-PCR for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003; 17(12): 2318–2357.
Hochhaus A., Larson R. A., Guilhot F. et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017; 376(10): 917–927.
Mahon F. X. Treatment-free remission in chronic myeloid leukemia: who, how, and why? Hematology Am Soc Hematol Educ Program. 2017; 2017(1): 102–109.
Sawyers C. L. Chronic myeloid leukemia. N Engl J Med. 1999; 340(17): 1330–1340.
Soverini S., De Benedittis C., Papayannidis C. et al. Molecular response milestones in chronic myeloid leukemia: revisiting the concept. Leukemia. 2021; 35(7): 1862–1870.